Newsletter | December 16, 2020

12.16.20 -- Strategies For Advancing Poorly Bioavailable Molecules

Technology Selection For Bioavailability Enhancement

Due to the growing incidence of low drug solubility in the pharmaceutical discovery and development pipeline, the number of enabling technologies that are employed to improve oral drug absorption and bioavailability (BA) are growing. Rational selection methodologies across this array of technologies can improve chances of clinical success, reduce program complexity, and accelerate development timelines.

In Vitro Test Methodologies For Characterizing Bioavailability Enhancing Formulations

Improved methods are needed to evaluate the effectiveness of bioavailability enhancement approaches. This presentation covers the development of in vitro tools for characterizing bioavailability enhancing formulations, criteria for selecting the optimal in vitro methods based on compound properties and dose, and case studies for multiple low solubility compounds.

High-Loaded Dosage Forms: Novel Platform Expands Dispersion Utility

Spray-dried amorphous solid dispersions (ASDs) show enormous promise in the delivery of drug compounds with low solubility. A novel platform expands the utility of this approach, enabling creation of ASD solid dosage forms with high drug loadings to meet patient needs.

Lipid-Based Formulations For Early-Stage Clinical Trials

For certain molecules, the most appropriate technology for bioavailability enhancement and accelerated development will be lipid-based formulations (LBF), supported by in silico development tools. Senior formulation and product development scientists analyze the potential benefits and applications of lipid/liquid-based formulations and how they may reduce timelines to clinical trials.

Reference Material